Microcirugía de glaucoma con el implante Preserflo.Fluídica experimental, morfología de la ampolla de filtración, cambios biométricos y corneales

Abstract

The reduction of intraocular pressure (IOP) has been proved the only valid treatment for glaucoma, which is the main cause for irreversible blindness worldwide. In a recent study carried outby the GBD 2019 Blindness and Vision Impairment Collaborators, among the global 33.6 million adults aged 50 years and older who were blind in 20203 the second leading cause of blindness was glaucoma (3.6 million cases, ranging from 2.8 to 4.4) after cataract. The gold standard for glaucoma surgery is trabeculectomy, described and applied since the mid-1960s,but new surgical methods less invasive have been developed in order to reduce adverse events. One of the two micro-filtering glaucoma surgery devices available in the market is the Preserflo Microshunt (Santen Pharmaceutical Company Ltd, Osaka, Japan). This is an aqueous drainage shunt to be implanted ab externo to create a full-thickness fistula from the anterior chamber across to the subconjunctival space...